A phase II study of pacritinib in patients with myelofibrosis demonstrated that pacritinib is active in patients with myelofibrosis, resulting in spleen volume reduction, while producing substantial and prolonged improvement in disease-related symptoms without causing clinically significant myelosuppression.
As a science journalist living in the epicenter of the measles outbreak, I did what any reporter would do when I was assigned this story—I texted my medical friends.
